India’s first intranasal Covid vaccine by Bharat Biotech received approval from the Drug Controller General of India (DCGI) for primary immunization against the injection for people above the age of 18. It is India’s first nasal vaccine for COVID-19. The Union Minister of Health and Family Welfare Mansukh Mandaviya termed the vaccine a ‘Big Boost’ to India’s fight against COVID-19.
Bank Maha Pack includes Live Batches, Test Series, Video Lectures & eBooks
Bharat Biotech International Limited (BBIL), is a global leader in vaccine innovation and developer of vaccines for infectious diseases. The BBIL announced that the development of the Intranasal COVID vaccine (BBV154), has been approved for restricted use in an emergency. The iNCOVACC, is a recombinant replication-deficient adenovirus vectored vaccine with a pre-fusion stabilized spike protein. This vaccine was evaluated in phases I, II, and III, clinical trials with successful results. The vaccine was formulated to allow Intranasal delivery through nasal drops. It is designed to be cost-effective in low and middle-income countries.
India has many cities known for their unique identity, and some of them are famous…
Global credit rating agency Fitch Ratings has revised India’s GDP growth forecast for FY26 to…
In a landmark shift in Pakistan’s military command structure, Field Marshal Asim Munir has been…
India’s Smart Cities Mission (SCM), launched in 2015, is entering its final stretch with an…
Welcome to the November 2025 Edition of the Affairs PDF – your all-inclusive monthly guide to…
The Reserve Bank of India (RBI) recently announced two major liquidity measures, a ₹1 trillion…